LG Chem Ltd. has synthesized new melanocortin 4 (MC4) receptor agonists reported to be useful for the treatment of obesity, diabetes, erectile dysfunction and inflammatory disorders.
Aptabio Therapeutics Inc. has identified new pyrazole derivatives acting as reactive oxygen species (ROS) production inhibitors reported to be useful for the treatment of cancer, neurodegeneration, fibrosis, liver diseases and dermatological, eye and inflammatory disorders, among other disorders.
Oncolinx Pharmaceuticals LLC and the U.S. Department of Health and Human Services have presented new signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, and bacterial and viral infections.
Research Triangle Institute (RTI International) has described new heteroaryl derivatives acting as apelin receptor (angiotensin-receptor like 1; APJ) agonists reported to be useful for the treatment of lung fibrosis.
Blossomhill Therapeutics Inc. has divulged macrocyclic compounds acting as epidermal growth factor receptor (EGFR: HER1; erbB1) and EGFR mutant inhibitors reported to be useful for the treatment of cancer.
Invenra Inc. has announced preclinical data supporting the ongoing development of INV-322, a Sniper bispecific antibody co-targeting CTLA-4 and CD25 for cancer developed using Invenra's B-Body Platform.
A series of novel tacrine derivatives acting as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor subtype antagonists has been developed in research seeking to exploit these targets for the treatment of Alzheimer's disease.
Researchers from the U.K. have investigated the specificity and sensitivity of clonidine growth hormone (GH) as a biomarker for the differential diagnosis of multiple system atrophy (MSA) from pure autonomic failure (PAF), Parkinson’s disease (PD) and progressive supranuclear palsy (PSP).
Researchers from Sun Yat-sen University, Southern Medical University and Gannan Medical University reported the discovery of novel quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
RSS
